An Animal Model of Emotional Blunting in Schizophrenia by Pietersen, Charmaine Y. et al.
An Animal Model of Emotional Blunting in Schizophrenia
Charmaine Y. Pietersen
1*
¤a, Fokko J. Bosker
1, Janine Doorduin
1, Minke E. Jongsma
1¤b, Folkert Postema
1, Joseph V. Haas




1¤c, Johan A. den Boer
1
1Graduate School of Behavioral and Cognitive Neuroscience, Department of Psychiatry, University Medical Center Groningen, University of
Groningen, Groningen, The Netherlands, 2Eli Lilly and Company, Indianapolis, Indiana, United States of America
Schizophrenia is often associated with emotional blunting—the diminished ability to respond to emotionally salient stimuli—
particularly those stimuli representative of negative emotional states, such as fear. This disturbance may stem from
dysfunction of the amygdala, a brain region involved in fear processing. The present article describes a novel animal model of
emotional blunting in schizophrenia. This model involves interfering with normal fear processing (classical conditioning) in rats
by means of acute ketamine administration. We confirm, in a series of experiments comprised of cFos staining, behavioral
analysis and neurochemical determinations, that ketamine interferes with the behavioral expression of fear and with normal
fear processing in the amygdala and related brain regions. We further show that the atypical antipsychotic drug clozapine, but
not the typical antipsychotic haloperidol nor an experimental glutamate receptor 2/3 agonist, inhibits ketamine’s effects and
retains normal fear processing in the amygdala at a neurochemical level, despite the observation that fear-related behavior is
still inhibited due to ketamine administration. Our results suggest that the relative resistance of emotional blunting to drug
treatment may be partially due to an inability of conventional therapies to target the multiple anatomical and functional brain
systems involved in emotional processing. A conceptual model reconciling our findings in terms of neurochemistry and
behavior is postulated and discussed.
Citation: Pietersen CY, Bosker FJ, Doorduin J, Jongsma ME, Postema F, et al (2007) An Animal Model of Emotional Blunting in Schizophrenia. PLoS
ONE 2(12): e1360. doi:10.1371/journal.pone.0001360
INTRODUCTION
Glutamate and dopamine neurotransmitter systems are distributed
throughout the brain and motivate the two main hypotheses
underlying the etiology of schizophrenia. The dopamine hypoth-
esis has its origins in the observation that typical antipsychotics
(dopamine receptor antagonists) tend to ameliorate positive
symptoms [1–3]. In comparison, glutamate has been implicated
by virtue of the observation that administration of non-competitive
NMDA (N-methyl-D-aspartate) receptor antagonists, such as
phencyclidine (PCP) and ketamine, to healthy volunteers repro-
duces not only positive, but also many of the negative symptoms
and cognitive impairments seen in schizophrenia [4],[5]. There-
fore, in order to address the need for novel antipsychotics that
counteract negative symptoms and cognitive deficits associated
with chronic schizophrenia, there has been a shift in research from
modulating dopaminergic to glutamatergic systems [6].
Negative schizophrenic symptoms include deficits in emotional
processing, or emotional blunting, typified by the inability to
process fear adequately. In a simple conditioning task using
aversive emotional stimuli, for example, patients failed to develop
an increase in response frequency to aversively reinforced trials,
whereas healthy volunteers acquired a differential response to
reinforced versus non-reinforced trials [7] (see also [8],[9]). Many
schizophrenic patients manifest deficits in the recognition of fearful
faces [10–12] in addition to general abnormalities in the
processing and attribution of negative emotional states [13],[14].
One brain area that plays a central role in the processing of fear
is the amygdala [15],[16]. Importantly, bilateral damage to the
amygdala has been shown to impair the processing of fearful facial
expressions in otherwise healthy human subjects [17] and reduced
amygdala volumes have been found in schizophrenic patients [18–
21]. In fact, some neuro-imaging studies suggest that the positive
symptoms of schizophrenia are associated with increased amyg-
dala activity, whereas negative symptoms are associated with
hypoactivation [22],[23].
In line with the above observations, Aleman and Kahn [24]
propose a two-hit model of amygdala abnormalities in schizo-
phrenia, combining the glutamate neurotransmitter hypothesis
with amygdala dysfunction. They speculate that prolonged
activation of the amygdala during psychotic states (positive
symptoms) in the onset stages of schizophrenia could lead to
glutamate excitotoxicity, resulting in amygdala lesions and long-
term hypofunctioning (see also [25],[6]), which ultimately could
underlie the negative symptoms of the disorder.
In order to investigate deficits in emotional processing, we
examine fear conditioning in the rat—an animal that has provided
the basis for several extant models of schizophrenia [26–30].
Specifically, we attempt to simulate the putative amygdala
hypoactivation caused by glutamate excitotoxicity indirectly by
blocking the NMDA receptor. We achieve this by administering the
glutamate NMDA-receptor antagonist, ketamine, to rats prior to
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is consistent with many previous studies showing that the NMDA
receptor is involved in fear conditioning. Goosens and Maren [31],
for example, have shown that infusion of the NMDA antagonist D,
L-2-amino-5-phosphonovalerate (APV) into either the basolateral or
central nuclei of the amygdala blocks the acquisition of conditional
fear. We hypothesize that the hypoglutamatergic state induced by
ketamine administration will interfere with normal fear processing
due to abnormalities inbasic association of fear cuesin the amygdala
and related brain areas (see also [32],[33]).
To measure the effects of these manipulations, we examine a
behavioral assay of fear conditioning known as freezing (i.e.
absence of movement in response to conditioning), either in the
presence or absence of administered ketamine. We also measure
two neural assays of fear conditioning within two separate regions
of the amygdala (the central [CEA] and basolateral nuclei [BLA]).
One assay is cFos expression—a measure of learning-related
neural activity [34]. The second assay is neurotransmitter tissue
content, which indicates the amount of neurotransmitter (intra-
and extracellular) in a given brain region.
In addition to the amygdala, we also examine various brain
areas associated with emotional processing, including the anterior
cingulate cortex (ACC) and the nucleus accumbens (core and shell,
Nacc). The rat ACC, a sub-area of the prefrontal cortex, has
previously been shown to be involved in associative learning,
particularly fear conditioning [35],[36], and in cognitive processes,
such as attention [37],[38]. Lesions of this area in humans produce
symptoms including apathy, inattention, dysregulation of auto-
nomic function and emotional instability [39], all symptoms
present in schizophrenic patients. The Nacc has also been
implicated in the neurobiology of schizophrenia [27] and is an
area primarily involved in motivation [40],[41]. It is also
intimately linked with the ACC [27],[37] and BLA [42] and
receives glutamatergic projections from these areas.
It has previously been reported that ketamine administration, in
addition to affecting the glutamate system, also affects the
dopamine system [43],[44]. Dopamine D2 receptor antagonists
have also been found to ameliorate ketamine-induced impairment
of some prefrontal cortex-dependent cognitive functions in rodents
[45]. A single-neurotransmitter perturbation is therefore probably
not sufficient to fully describe the emotional deficits reflected in the
schizophrenic brain. Therefore, both neurotransmitter systems
implicated in the origins of schizophrenia, as well as their
interactions, are investigated here (i.e. through measurement of
neurotransmitter tissue content).
In order to validate the etiological aspects of our model, we
administer two antipsychotics used in the clinical setting, haloperidol
and clozapine. Haloperidol, a typical antipsychotic, is used for
treating positive symptoms of schizophrenia [1],[46],[2] [3].
Clozapine, in contrast, is an atypical antipsychotic that has been
found to alleviate negative and cognitive symptoms of schizophrenia
[6]. Clozapine also differs from conventional neuroleptics, such as
haloperidol, in the way it affects the glutamate system [47],[6]. For
example,animal studies haveshown anincrease inmedialprefrontal
cortical glutamate concentrations after clozapine administration,
while haloperidol did not elicit this increase [48]. Another animal
study, comparing the effects of haloperidol and clozapine on
ketamine-induced alterations in metabolism, found that clozapine
completely blocked the effects of ketamine in several brain areas,
whereas haloperidol did not [49]. We therefore hypothesize that
clozapine, but not haloperidol, will retain the behavioral changes
induced by fear conditioning following ketamine administration. We
also administer a new compound (LY 379268; (-)-2-Oxa-4-
aminobicyclo [3.1.0.] hexane-4,6-dicarboxylate), a metabotropic
glutamate2/3-receptoragonist,whichiscurrentlybeingtestedforits
involvement in fear learning [50]. It is presently unclear whether LY
379268 can affect conditional fear processing in the rat. A recent
study, however, does suggest that agonists of this receptor possess
anxiolyticproperties[51].Themetabotropicglutamate2/3-receptor
is located primarily in forebrain regions, and LY 379268 has been
shown to decrease glutamate release in these areas [52]. We
therefore postulate that LY 379268, as a glutamate agonist, will
inhibit ketamine’s actions on glutamate content, especially in
forebrain areas, in line with similar studies in the literature [53–55].
To summarize, we hypothesize that the influence of ketamine on
fear conditioning will manifest itself as a decrease in neuronal
activity, relative to fear-conditioned saline controls, in brain regions
associated with fear processing, in addition to inhibiting behaviors
typically derived from fear conditioning. We also hypothesize that
ketamine will interfere with the neurochemical alterations in brain
areas associated with fear conditioning, primarily through action on
NMDAreceptorsintheamygdala.Further,weexpectthatclozapine
willpreservenormalfear-conditionedbehaviorand neuronalactivity
abolished by ketamine. We also hypothesize that haloperidol, as it
mainly affects positive symptoms, will not inhibit ketamine’s actions
in these assays. We also tentatively postulate that LY 379268 will
prevent ketamine’s actions assessed in the above-mentioned assays,
mainly in forebrain areas. Evidence in favor of these hypotheses
would support the notion that glutamatergic hypofunctioning in the
amygdala and related brain areas underlies negative schizophrenic
symptoms, therebypaving the wayfor future studies to explorenovel
drug treatments of these notoriously drug-resistant symptoms.
MATERIALS AND METHODS
Two experiments were conducted to measure the alterations in
behavior, cFos expression and neurotransmitter content due to
fear conditioning and ketamine and/or antipsychotic administra-
tion. This was done because the same animals could not be used
for both experiments due to methodological constraints.
Animal Housing
All animals were cared for in accordance with the principles laid
down by the European Communities Council Directive (1986) for
the Protection of Vertebrate Animals used for Experimental or
Other Scientific Purposes (86/EEC), which is comparable to the
guidelines laid down in the ‘‘Principles of laboratory and animal
care.’’ Male Sprague-Dawley rats weighing between 225–250 g
were obtained from the central animal facility (Groningen, The
Netherlands) and were housed individually in a temperature
(623uC) and humidity controlled (40 to 60%) environment. Food
and water were delivered ad libitum.
Drugs
Haloperidol (0.25 mg/kg, i.p.) was diluted from 5 mg/1ml HaldolH
injection capsules. Both clozapine (5 mg/kg, i.p.) and ketamine
(16 mg/kg, s.c.) were dissolved in physiological saline (0.9%), with
hydrochloric acid (HCL) added to clozapine to aid dissolving. One
ml/ml of 5N sodium hydroxide (NaOH) was added to the LY
379268 (3 mg/kg, s.c.) in saline solution before sonication, also for
dissolving purposes. Antipsychotics were administered 30 minutes
prior to ketamine, in accordance with previous studies investigating
the effects of antipsychotics on NMDA antagonists [56–58]. All drug
doses were determined empirically, i.e. it was the highest dose
possible that did not affect locomotor behavior or induce catalepsy,
except ketamine (see below). The clozapine and haloperidol doses
are in line with the clinical setting, as determined by D2 receptor
occupancy [59]. Clozapine was obtained from Sandoz Pharma AG,
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379268 from Eli Lilly, USA; and ketamine hydrochloride from
Sigma, Germany.
Shock Construct
The shock box was a specially constructed wooden container with
a floor made of a metal grid. A central computer controlled the
current and tone emission making use of a program that was
specially developed for this study (N594 version 2.00, University of
Groningen, The Netherlands, 2002). All shock trials took place in
the mornings. Rats destined to undergo fear conditioning were
subjected to a shock (1.5 mA) that was paired with a tone (60 dB
tone) during conditioning trials (Fig. 1). This shock intensity was
based on a pilot study indicating that 1.0 and 1.5 mA shocks
induced comparable stress levels (corticosterone and behavior), but
that the latter shock intensity was superior in terms of variability of
all incurred stress parameters [60].
Fear conditioning paradigm
After arrival from the animal breeding facility, rats were allowed to
acclimatize for two to three days. They were then handled daily
for five days in order to eliminate handling stress as a confounding
variable. All drug injections only took place on the first two days of
the three-day conditioning paradigm, i.e. only during the actual
conditioning phase of the experiment. Injections were omitted on
the third day of conditioning testing to avoid unnecessary drug
interaction with behavioral measurements. Specifically, haloperi-
dol, clozapine and LY 379268 were administered half an hour
before ketamine injections in experiment 1 (see Fig. 1). Only
clozapine was used in experiment 2 and was injected at the same
time point as in experiment 1. Ketamine injections and saline
shams were administered half an hour before fear conditioning, as
previous observations in our lab showed that half an hour was
sufficient for ketamine-induced increases in locomotor activity to
subside [61].
The rats were subsequently placed individually in the shock box.
One trial consisted of a 1-minute period. We presented rats with a
toneduringthefirst 15 seconds. In thenext 15 seconds, thetone was
emitted in combination with a shock. Thirty seconds thereafter, the
process was repeated. This 1-minute trial was repeated 10 times per
day in succession, resulting in one session of 10 minutes (or 10 trials).
This protocol was repeated on day 2. Control rats followed the same
routine with tone emission, but without experiencing any shocks,
essentially following a timed tone protocol. On day 3, neither group
received shocks or injections; otherwise the animals follow the same
protocol. This was done to avoid measuring behavioral outputs due
to direct drug interference or pain stimuli.
Following this fear conditioning paradigm, behavior was
recorded (Philips Explorer Camcorder) for 5 minutes after the
test session (experiment 1) on the third day in order to determine if
a fear response was acquired in reaction to the whole stress
procedure (tone and context). Previous studies in our lab
(unpublished data) have shown that minimal extinction occurs
during the first 5 minutes after the last test session and that fear-
conditioned freezing behavior was still evident. In order to
adequately estimate the immediate effects of altered neurotrans-
mitter content (which degrades quickly) on behavior, freezing was
measured during, rather than after, the test session in experiment 2
and animals sacrificed 15 minutes thereafter.
Behavioral measurements
Behaviors were subsequently analyzed with The Observer (Noldus
version 3.0, The Netherlands). An independent observer, unaware
of experimental conditions, noted both the frequency and total
duration of freezing (experiments 1 and 2), grooming, rearing and
resting behavior (experiment 1). Freezing was denoted as an
absence of any movement (not sleeping), except for respiration and
whisker twitching. Rearing was defined as the raising of the body
onto the hind legs, while resting served as a default state when
none of the other behaviors were being displayed (i.e. normal
ambulatory behavior). Freezing behavior, as well as being a
behavioral expression of stress, is also the main assay of fear
conditioning [62],[63]. As this parameter gave the best results in
experiment 1, we eliminated all other behavioral measurements
from the design in experiment 2.
Design of Experiment 1
The rats (n=48) were divided into seven groups as illustrated in
Fig. 2. At the top of the hierarchy, we had a fear conditioned (FC,
n=6) group, a fear conditioned with ketamine administration
(FC+Ket, n=6) group, a non-fear-conditioned (NFC, n=12)
group, and a non-fear-conditioned group that received ketamine
(n=6). An additional four groups receiving the FC+Ket treatment
also received antipsychotics; each group received either a
clozapine (FC+Ket+CLOZ; n=6), haloperidol (FC+Ket+HALO;
n=6), or LY 379268 (FC+Ket+LY; n=6) injection, in addition to
ketamine and fear conditioning.
cFos expression: perfusion and preparation
One hour after the end of the test session (day 3), the rats were
perfused trans-cardially with 4% paraformaldehyde (Merck, Ger-
many) for 20 minutes. This time point was chosen so as to
incorporate all events happening in the brain during the tone signals
in the testing session on day 3 [64]. The brains were then removed
and placedinto4%paraformaldehyde,andkeptat 6uCfo rt woda ys .
Thereafter, they were transferred into 0.02 M potassium phosphate
buffered saline(PBS;pH 7.4)with1%sodiumazide(Boom,Meppel,
The Netherlands) to prevent bacterial growth and were stored at
6uC. In preparation for cFos staining, whole brains were dehydrated
in a 30% sucrose solution overnight and subsequently frozen with
gaseous CO2 at 280uC. The brains were cut using the Leica CM
3050 cryostat machine at 40 micrometers thin slices and stored at
6uC in 0.02 M PBS buffer (pH 7.4).
cFos staining: Immunocytochemistry
Coronal cryostat sections of 40 mm were collected in 0.01 M Tris
buffered saline (TBS, pH 7.4) and rinsed 3 times, 5 minutes per
rinse (365 min). After pre-incubation with 0.3% H2O2 (10 min, in
0.01 M TBS, pH 7.4), the sections were washed with 0.01 M TBS
(465 min, pH 7.4) and incubated with a rabbit polyclonal
antibody raised against cFos (Ab-5 Oncogene Research Products,
Calbiochem, 1:10.000 in 0.01 M TBS-Triton 0.01%, 4% normal
goat serum) for 48–60 hours at room temperature. Subsequently,
the sections were washed in 0.01 M TBS (865 min, pH 7.4) and
incubated for 2 hours at room temperature with biotinylated goat
anti-Rabbit IgG (Vector, 1:1000 in 0.01 M TBS). After rinsing
with 0.01 M TBS (665 min, pH 7.4), the immunoreactivity was
visualized with a standard ABC method (Vectastain ABC kit,
Vector, (1 drop A+1 drop B)/20 ml TBS for 2 hours). After
washing with TBS 0.01 M (665 min, pH 7.4) the peroxidase
reaction was developed with a di-aminobenzidine (DAB)-nickel
solution and 0.3% H2O2 (0.5 mg DAB/ml Distilled water; 1.0%
nickel ammonium sulphate (NAS)) in 0.1 M sodium acetate
(NaAc, pH 6.0). To stop the reaction, the sections were washed
with 0.1M NaAc, pH 6.0 (365minutes) and then 0.01 M TBS
(365 min, pH 7.4) and were subsequently mounted on gelatin-
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(Gurr) (Boom, Meppel, The Netherlands).
The area of the region of interest was measured and, after
background correction, the number of immunopositive nuclei
was quantified using a computerized image analysis system (Leica
Qwin version 2.3, Leica Microsystems Imaging Solutions). The
average number of cFos immunoreactive cells was calculated and
expressed as number of positive nuclei or Counts/Area
(0.1 mm
2). Areas included in the cFos analysis were: the
paraventricular nucleus (PVN), CEA, BLA (subdivided into
anterior and posterior nuclei) and lateral nucleus of the
amygdala, Nacc (core and shell), and ACC. The Swanson [65]
co-ordinates (rostral-caudal) are given in Table 1 as millimeters
from Bregma.
Figure 1. Injection and shock schedule. One trial consisted of a 30 second period. During the 30 seconds, a tone was emitted. Within the second
half (15 seconds) of this 30-second period, the shock was delivered. Thirty seconds following the trial served as a rest period. All trials took place in
the morning and were repeated consecutively ten times per day, resulting in one session lasting 10 minutes in total. Control rats followed the same
routine with tone emission, but without experiencing any shocks. On the third day, the same procedure was followed, but without administering
shocks. This was done to avoid measuring behavioral outputs due to direct drug interference or pain stimuli. Experiment 1: n=48; experiment 2: n=29
doi:10.1371/journal.pone.0001360.g001
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Due to the presence of occasional outliers, the behavioral data
were analyzed by one-way analysis of variance (ANOVA) on rank-
transformed data, which is equivalent to the Kruskal-Wallis test
[66]. When the overall F test of treatment group equality was
significant at the 5% level (p,0.05), planned comparisons among
treatment groups were made with the LSD (least significant
difference) pairwise comparisons method. When the overall F test
was not significant at the 5% level, planned comparisons were
made with the Bonferroni method [67].
An independent Student’s t-test was first applied to the cFos data
with regards to the FC and NFC groups to determine if there was an
effect of fear conditioning. This was done in order to determine
which brainareas weretobefurther analyzed for data collection and
which could be discarded. If a fear conditioning effect was found
(p,0.05), all groups were then counted in appropriate brain areas
revealed by the t-test and subsequently analyzed by means of a one-
way analysis of variance (ANOVA), followed by post-hoc LSD
pairwise comparisons. Logged equivalents were used in order to
eliminate skew distributions where necessary.
The set of planned comparisons were as follows: FC vs. NFC; FC
vs. FC+Ket; NFC vs. Ket; FC+Ket vs. FC+Ket+Cloz; FC+Ket vs.
FC+Ket+Halo; and FC+Ket vs. FC+Ket+LY. Statistical analyses
were performed with JMP Release 5.1.1 software or SPSS v.12.
Design of Experiment 2
The rats were divided into 5 groups: sham control (NFC), fear
conditioned (FC), FC+ketamine (Ket), FC+clozapine (Cloz) and
FC+Ket+Cloz. Clozapine was obtained from Sandoz Pharma AG,
Switzerland and ketamine hydrochloride from Sigma, Germany.
Tissue collection and punching technique
Fifteen minutes after the test session (day 3), rats were
anaesthetized with 5% isoflurane and decapitated; brains were
quickly removed and frozen in 280uC. Serial 300 mm coronal
sections were made with a cryostat microtome (215uC) and frozen
on dry ice. We identified several fear processing regions
[37],[68],[16],[50]. Tissue samples were therefore dissected from
the ACC, Nacc, PVN, CEA and BLA, dentate gyrus (DG), dorsal
raphe (DR) and locus coeruleus (LC; Fig. 5). The Swanson [65]
co-ordinates are given in Table 1.
Dissections were made using a needle punch technique on frozen
coronal sections. Three different needle diameters were used in
accordance with the size of the area to be punched. Larger areas,
such as the ACC, Nacc, PVN and DR, were punched with a 16G
needle (1.6640 mm; Sterican, B.Braun, Germany; one
punch<0.23 mm
2), while the DG, LC (18G: 1.2638 mm; Sterican,
B.Braun, Germany; one punch<0.19 mm
2) and the amygdala
Figure 2. Experimental group divisions. Diagram portraying the rat group divisions. At the top of the hierarchy, we divided rats into two main
groups: those receiving fear conditioning, and those not. Those animals receiving fear conditioning, were then further divided into rats receiving
ketamine administration and rats receiving saline shams. The latter group would form the fear conditioning only group (FC). The rats not receiving
fear conditioning were also divided into two groups depending on whether they would receive a ketamine or saline injection; the former group
making up the ketamine only group (Ket), and the latter being the control group (NFC). The remaining fear conditioned rats also receiving ketamine
were then further divided into those receiving either a saline injection (FC+Ket) or those receiving an additional antipsychotic injection consisting of
clozapine (FC+Ket+CLOZ), haloperidol (FC+Ket+HALO), or LY 379268 (FC+Ket+LY). CLOZ, clozapine; FC, Fear conditioning; HALO, haloperidol; KET,
ketamine; LY, LY379268; NFC, no fear conditioning; SAL, saline.
doi:10.1371/journal.pone.0001360.g002
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punch<0.08 mm
2) were punched with smaller diameter needles.
Approximately two punches were taken per hemisphere, per animal.
Tissue was homogenized in 100 ml (0.1 M) perchloric acid and then
the suspension was centrifuged (13,500 rpm) for 10 minutes. The
supernatant was stored at 280uC until further analysis.
Dopamine and glutamate analysis
Analysis of dopamine and its metabolite dopac, was performed by
a Shimadzu LC-10 AD high performance liquid chromatograph
equipped with a 15-cm reversed phase column (supelcosil 3 mm,
C18, 15064.60 mm, Bester, Amstelveen, The Netherlands) and
an electrochemical detector (ESA, Chelmsford, MA, USA) at a
potential setting of 300 mV. The mobile phase consisted of 10%
methanol, 4.2 g sodium acetate/l, 150 mg octane sulphonic acid/l
adjusted to pH 4.10. The injection volume was 20 ml and the flow
rate 1 ml/min.
Analysis of glutamate was performed after derivatization with
ortho-phtaldehyde by a Shimadzu LC-10 AD high performance
liquid chromatograph equipped with a 15-cm reversed phase
column (supelcosil 3 mm, C18, 15064.60 mm, Bester, Amstelv-
een, The Netherlands) and a fluorescence detector (Waters 470,
fluorescence detection, Waters, Milford, Massachusetts, USA) with
extinction and emission wavelengths set at 350 nm and 450 nm,
respectively. The mobile phase consisted of 26% methanol, 10 g/l
disodiumhydrogenphosphate (Na2HPO4), 150 mg/l EDTA,
2.19 ml/l tetrahydrofuran and adjusted to pH 5.27. The injection
volume was 20 ml and the flow rate 1ml/min.
Statistics for Experiment 2
The overall group effect was assessed via one-way analysis of
variance (glutamate, dopamine) or the Kruskall-Wallis test for
non-parametric data (dopac, behavior) using SPSS (Version 12).
Parametric vs. non-parametric tests were chosen on the basis of
normal distribution curves. When the overall F test of treatment
group equality was significant at the 5% level (p,0.05), planned
LSD pairwise comparisons were made among treatment groups
(glutamate, dopamine) and Mann-Whitney U test (dopac,
behavior) with significance determined at the p,0.05 level.
RESULTS
Behavioral data from Experiment 1
The total duration and frequency of behaviors 5 minutes after the
test session were analyzed, and are represented in Fig. 3
(Experiment 1). The behaviors of 3 rats in the control group were
not included due to technical difficulties with the video recording.
The one-way ANOVA revealed significant overall differences for
the following behaviors: resting duration (F6, 38=3.32; p=0.0099)
and frequency (F6, 38=15.23; p,0.0001), freezing duration (F6,
38=6.51; p,0.0001) and frequency (F6, 38=20.42; p,0.0001),
and rearing duration (F6, 38=6.79; p,0.0001) and frequency (F6,
38=5.35; p=0.0004).
The LSD pairwise comparisons post hoc showed fear-
conditioning effects in most of the behaviors investigated (FC vs.
NFC). These include a decrease in resting duration (p=0.0064;
Fig. 3A), and increases in rearing duration (p=0.0262; Fig. 3A)
and resting frequency (p,0.0001; Fig. 3B). More importantly,
increases in freezing duration (p=0.0001; Fig. 3A, C) and
frequency (p,0.0001; Fig. 3B, D) were noted.
Ketamine alone did not influence any of the behaviors
measured (data not shown). It augmented the effect of fear
conditioning with respect to rearing duration (p=0.0023). In
agreement with our hypothesis, however, ketamine blocked the
effects of fear conditioning with respect to both freezing duration
(p=0.0213; Fig. 3C) and frequency (p=0.0002; Fig. 3D).
Comparing the effect of antipsychotics on rats undergoing fear
conditioning with ketamine administration (FC+Ket vs.
FC+Ket+Cloz/Halo/LY), we find significant differences with
respect to rearing duration. Decreases in rearing duration were
noted due to clozapine (p=0.0123) and haloperidol (p=0.0043)
administration, both blocking the effect of ketamine (data not
shown). While antipsychotics did not inhibit the effect of ketamine
on fear conditioning with respect to freezing duration (Fig. 3C),
haloperidol (p=0.0040) and LY 379268 (p=0.0026), but not
clozapine (p=0.1033), did block the effect of ketamine with
respect to freezing frequency (Fig. 3D).
cFos data from Experiment 1
Results of the cFos data are represented in Fig. 4, with typical
examples of cFos stainings and the delineations of the areas
represented in Fig. 5. An independent Student’s t-test revealed
fear-conditioning effects in the ACC (p=0.016), Nacc shell
(p=0.001), and the PVN (p,0.0001). No fear conditioning effects
were noted in the Nacc core (p=0.649) and therefore this area was
not included for further analyses. With regards to the amygdala,
significant fear conditioning effects were found in the anterior
portion oftheBLA(p=0.008)andlateralamygdala (p=0.008), with
no effects of fear conditioning in the (medial) central amygdala
(p=0.654)or the posterior portion of the BLA (p=0.483). The latter
two areas were therefore not included in further analyses. The one-
way ANOVA revealed significant overall F-tests performed on the
remaining groups for the following brain areas: ACC (F6, 39=5.96;
p,0.001), Nacc shell (F6, 40=8.96; p,0.001), PVN (F6, 40=25.89;
p,0.001), anterior BLA (F6, 39=9.49; p,0.001) and lateral
amygdala (F6, 39=11.68;p,0.001).
The LSD pairwise comparisons post hoc showed increases in
cFos expression due to fear conditioning (NFC vs. FC) in all
remaining brain areas: ACC (p=0.003; Fig. 4A), Nacc shell




Area mm from Bregma
Anterior cingulate +2.80 to 2.15
Anterior basolateral nucleus amygdala 22.45 to 22.85
Central nucleus amygdala 22.45 to 22.85
Lateral nucleus amygdala 22.45 to 22.85
Nucleus accumbens: core and shell +2.80 to 0.45
Paraventricular nucleus 21.53 to +2.00
Posterior basolateral nucleus amygdala 22.45 to 22.85
EXPERIMENT 2
Anterior cingulate +2.80 to 2.15
Basolateral nucleus amygdala 22.45 to 22.85
Central nucleus amygdala 22.45 to 22.85
Dentate gyrus 22.45 to 22.85
Dorsal raphe 27.10 to 28.60
Locus coeruleus 29.60 to 210.10
Nucleus accumbens +2.80 to 0.45





















































































Animal Model of Schizophrenia
PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1360Figure 3. Behavioral data. Experiment 1 (behavior measured after test session): Bars represent means6SEM. Fear conditioning affects almost all of
the behaviors including a decrease in resting duration (p=0.0064; A), and increases in rearing duration (p=0.0262; A), resting frequency (p,0.0001;
B), and freezing duration (p=0.0001; A) and frequency (p,0.0001; B). As hypothesized, ketamine blocked the effect of fear conditioning (FC vs.
FC+Ket), reducing freezing duration (p=0.0213; C) and frequency (p=0.0002; d). Haloperidol (p=0.0040) and LY 379268 (p=0.0026) were able to
partially inhibit this blockade (FC+Ket+Halo/LY vs. FC+Ket), but only in terms of freezing frequency (D). Experiment 2 (behavior measured during test
trial): Fear conditioning increased (E) total freezing duration and (f) freezing frequency as compared to the NFC group. Ketamine blocked this effect
(FC vs. FC+Ket) in terms of the total duration and freezing frequency. Clozapine alone (FC vs. FC+Cloz) reduced (F) freezing frequency. The
FC+Ket+Cloz group was also not statistically different from the FC+Ket group in terms of freezing behavior. Cloz, clozapine; FC, Fear conditioning; Halo,
Haloperidol; Ket, Ketamine; LY, LY 379268; NFC, no fear conditioning.
doi:10.1371/journal.pone.0001360.g003
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1360(p,0.0001; Fig. 4B), and PVN (p,0.0001; Fig. 4C). More
importantly, increases due to fear conditioning were noted in the
anterior portion of the BLA (p=0.002; Fig. 4D) and lateral
amygdala (p,0.0001; Fig. 4E).
Ketamine led to the hypothesized blocking of cFos expression due
to fear conditioning (FC vs. FC+Ket) in all the brain areas
investigated, i.e. the ACC (p,0.0001), Nacc shell (p=0.002), PVN
(p,0.0001), anterior BLA (p=0.001) and lateral amygdala
Figure 4. cFos expression. Fear conditioning (FC) increased cFos expression as compared to the NFC group in the anterior cingulate (p=0.003; A),
nucleus accumbens shell (p,0.0001; B), and paraventricular nucleus (p,0.0001; C), anterior basolateral amygdala (p=0.002; D) and lateral amygdala
(p,0.0001; E). Ketamine blocked the effect of fear conditioning (FC vs. FC+Ket) in the anterior cingulate (p,0.0001; A), nucleus accumbens shell
(p=0.002; B), paraventricular nucleus (p,0.0001; C), anterior basolateral amygdala (p=0.001) and lateral amygdala (p=0.004). As hypothesized,
clozapine was able to counteract the blockade of ketamine on fear conditioning (FC+Ket vs. FC+Ket+Cloz) in the anterior cingulate (p,0.0001),
nucleus accumbens shell (p=0.001), paraventricular nucleus (p=0.001), anterior basolateral amygdala (p,0.0001) and lateral amygdala (p,0.0001).
A slight restoration by haloperidol was noted in the anterior cingulate (p=0.042). Cloz, clozapine; FC, fear conditioning; Halo, haloperidol; Ket,
Ketamine; LY, LY 379278; NFC, no fear conditioning.
doi:10.1371/journal.pone.0001360.g004
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PLoS ONE | www.plosone.org 8 December 2007 | Issue 12 | e1360(p=0.004). Decreases of cFos expression due to ketamine alone
(without fear conditioning; data not shown) were also noted in most
areas except the ACC (p=0.087) and Nacc shell (p=0.09), i.e. PVN
(p=0.047),anteriorBLA(p=0.003)andlateralamygdala(p=0.01).
It was also hypothesized that clozapine, and not haloperidol or
LY 379268 would block the effect of ketamine on fear
conditioning (FC+Ket) with regards to cFos expression. These
hypotheses were supported by the data, which showed normal fear
conditioning effects on cFos expression with clozapine adminis-
tration. Significant differences between groups due to clozapine
administration (FC+Ket vs. FC+Ket+Cloz) were noted in the
ACC (p,0.0001), Nacc shell (p=0.001), PVN (p=0.001),
anterior BLA (p,0.0001) and lateral amygdala (p,0.0001).
Haloperidol did show some effect in the ACC, although not as
significant as clozapine (p=0.042). No other effects of haloperidol
or LY 379268 drugs were found in any of the other areas
investigated.
Behavioral data from Experiment 2
The Kruskall-Wallis test revealed an overall group effect for the total
duration of freezing behavior (x
2
4, 24=23.84;p,0.0001; Fig. 3E)
and frequency of freezing behavior (x
2
4, 24=17.35; p=0.002;
Fig. 3F). Mann-Whitney U post hoc tests showed a significant
increase in total duration spent freezing (p=0.004) and an increase
in frequency of freezing (p=0.004) in the fear conditioned (FC)
group relative to the non fear-conditioned group (NFC).
Ketamine significantly blocked the effects of fear conditioning
with respect to total duration (p=0.002) and frequency of freezing
behavior (p=0.004). Clozapine, however, was not able to reinstate
fear conditioning levels for either measure of freezing behavior
(duration: p=0.240; frequency: p=0.310). Clozapine alone
decreased freezing frequency (p=0.009) but not total freezing
duration.
Glutamate data from Experiment 2
Overall group effects were noted in all areas: ACC (F4, 48=6.46;
p,0.0001), Nacc (F4, 49=9.29; p,0.0001), PVN (F4, 22=6.29;
p=0.002), CEA (F4, 43=20.91; p,0.0001), BLA (F4, 48=8.91;
p,0.0001), DG (F4, 49=18.20; p,0.0001), DR (F4, 23=94.85;
p=0.006), and LC (F4, 48=14.45; p,0.0001).
LSD pairwise comparisons (data not shown) revealed increased
glutamate content in the FC vs. NFC group in all areas except the
ACC (p=0.099) i.e. Nacc (p,0.0001), PVN (p=0.012), DG
(p,0.0001), DR (p=0.003), and LC (p,0.0001). Highly signif-
icant increases in glutamate were noted in the CEA (p,0.0001)
and BLA (p,0.0001; Fig. 6A). Ketamine significantly reduced this
effect in these two areas, the CEA (p,0.0001) and the BLA
(p=0.041), in addition to the LC (p=0.008).
Clozapine prevented the effects of ketamine in the BLA
(p=0.001; Fig. 6A) and LC (p=0.017). Partial prevention was
seen in the CEA (p=0.088; Fig. 6A). A similar (non-significant)
pattern is noted in the PVN and DR. Interestingly, clozapine alone
(FC+Cloz), like ketamine, also blocked the increase in tissue
glutamate in the central amygdala (p,0.0001; Fig. 6A), and locus
coeruleus (p=0.007; data not shown) associated with fear
conditioning.
Figure 5. cFos immunocytochemical labeling. Typical examples of the brain areas stained for cFos expression, visually showing the effects of some
of the treatments. Delineated areas depict areas measured. Brain slice levels were taken from the Swanson rat brain atlas [65], with appropriate co-
ordinates listed in Table 1. CLOZ, clozapine; FC, Fear conditioning; KET, ketamine; NFC, no fear conditioning.
doi:10.1371/journal.pone.0001360.g005
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PLoS ONE | www.plosone.org 9 December 2007 | Issue 12 | e1360Figure 6. Neurotransmitter content. Bars represent means6SEM. The FC group showed increased glutamate levels (A) in the central and basolateral
amygdala, as compared to the NFC group. Ketamine also significantly inhibited this effect in both amygdala nuclei, as revealed by the comparison
between FC+Ket and FC groups. Clozapine, in turn, blocked the actions of ketamine on glutamate levels (FC+Ket versus FC+Ket+Cloz) in the central
amygdalanucleus,withfull restorationofnormalfear conditioned-inducedglutamate levels in thebasolateral amygdala. Clozapinealone (FC+Cloz vs. FC)
decreased glutamate levels in the central amygdala. In terms of dopamine content, there were no differences between the FC and NFC groups in either
amygdala nuclei (B). A decrease in dopamine content was, however, noted in the nucleus accumbens (C). Ketamine abolished this fear conditioning
response, and clozapine partially counteracted the effect of ketamine in the nucleus accumbens. Clozapine alone (no ketamine) also showed effects
(FC+Cloz), and increased dopamine content in the nucleus accumbens as compared to the FC group. Ketamine in combination with clozapine
(FC+Ket+Cloz; or alone (FC+Ket) increased dopamine levels in the central amygdala (B) as compared to the FC only group. Bla, basolateral amygdala
nucleus; cea, central amygdala nucleus; Cloz, clozapine; FC, fear conditioning; Ket, ketamine; nacc, nucleus accumbens; NFC, no fear conditioning.
doi:10.1371/journal.pone.0001360.g006
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PLoS ONE | www.plosone.org 10 December 2007 | Issue 12 | e1360Dopamine data from Experiment 2
Overall group analysis shows significant changes of dopamine
content in the ACC (F4, 40=4.18; p=0.006), Nacc (F4, 32=15.33;
p,0.0001), PVN (F4, 17=3.15; p=0.041), CEA (F4, 36=7.09;
p,0.0001), DG (F4, 17=5.92; p=0.004), DR (F4, 18=3.82;
p=0.02) and LC (F4, 41=5.79; p=0.001). No significance
differences were noted in the BLA in terms of dopamine content
(F4, 40=7.63; p=0.556).
Fear conditioning induced a decrease in dopamine content in
the Nacc (p=0.005; Fig. 6C) and an increase in the LC
(p=0.006). A trend towards increased dopamine content in the
ACC (p=0.056) is also noted. Ketamine was also able to abolish
this fear conditioning (FC+Ket vs. FC groups) response in the
Nacc (p,0.0001; Fig. 6C), while showing a trend at augmenting
the response of fear conditioning in the ACC (p=0.053) and LC
(p=0.103). As hypothesized, clozapine partially (b/c FC+K+Cloz
in Nacc is still significantly different than FC alone) counteracted
the effect of ketamine in these areas: ACC (p=0.044), Nacc
(p=0.011), and LC (p=0.008). Ketamine (p=0.002) increased
dopamine content in the CEA (Fig. 6B). Clozapine alone also
showed effects (FC+Cloz), increasing dopamine content in the
Nacc (p,0.0001; Fig. 6C) and PVN (p=0.049) as compared to
the FC group. Not enough data was available to perform post hoc
tests on the DG.
Dopac/Dopamine ratios from Experiment 2
The Kruskall-Wallis test showed overall group significances in the
ACC (x
2 (4, 40)=14.53; p=0.006), Nacc (x
2 (4, 30)=22.20;
p,0.0001) and CEA (x
2 (4, 35)=17.01; p=0.002). The Mann-
Whitney U test revealed an increase in turnover in the Nacc
(p=0.005) due to fear conditioning (Table 2). Ketamine also
decreased turnover in the Nacc (p=0.001) and the CEA
(p=0.008). Clozapine failed to prevent this deficit in both areas
(Nacc: p=0.518; CEA: p=315).
DISCUSSION
Summary of results
The main aim of this study was to investigate whether fear
conditioning was disrupted in rats following ketamine administra-
tion. We hypothesized that ketamine administration induces a
hypoglutamatergic state which models negative symptoms (deficits
in emotional processing) seen in schizophrenia. Aleman and Kahn
[24] proposed that prolonged activation of the amygdala, during
psychotic states in the onset stages of schizophrenia, could lead to
glutamate excitotoxicity. This would eventually result in amygdala
lesions and long-term glutamate hypofunctioning (see also [6]),
thereby disrupting a primary brain area in the fear circuit. By
administering the NMDA receptor antagonist ketamine, we
therefore attempted to simulate disrupted fear processing at a
neurochemical level.
We found that fear conditioning alone led to increases in 1) fear-
conditioned freezing behavior, 2) cFos expression in the ACC,
Nacc shell, PVN, and the anterior BLA and LA nuclei, and 3)
increased glutamate tissue content in some brain regions
measured, including the amygdala nuclei. Dopamine content
was not affected by fear conditioning in most of the brain areas
analyzed, with the exception of an increase in the LC and a
decrease in the Nacc. In addition, the Nacc showed an increase in
dopamine turnover (Table 2).
Ketamine successfully disrupted fear conditioning, both behav-
iorally and in the measured neural correlates of fear conditioning.
Indeed, freezing behavior was decreased almost to control levels.
This behavioral abolishment of fear conditioning was also reflected
in the ACC, Nacc shell, PVN, anterior BLA and the LA, in terms
of reduced cFos expression. Glutamate tissue content was also
attenuated down to control (no fear conditioning) levels in the
amygdala nuclei, although this was not found to be the case for the
ACC. Dopamine content was increased by ketamine administra-
tion in the CEA and the Nacc.
We also administered both an atypical and a typical
antipsychotic, in addition to a metabotropic glutamate 2/3-
receptor (mGlu2/3) agonist, LY 379268. As an atypical antipsy-
chotic, clozapine is considered to be useful in ameliorating
negative symptoms, whereas the typical antipsychotic, haloperidol,
mostly reverses positive symptoms. Other animal studies have
indicated that clozapine is successful in blocking metabolic effects
induced by ketamine [49], consistent with its action on NMDA
receptors. In the same experiment, haloperidol (a preferential
dopamine D2 receptor antagonist) was not able to block the effects
of ketamine. We therefore hypothesized that clozapine would be
capable of reversing the effects of ketamine, whereas haloperidol
would not. We also tentatively postulated that LY 379268 would
prevent ketamine’s actions, particularly in forebrain areas.
We found that clozapine administration entirely prevented cFos
expression due to subsequent ketamine administration (to fear
conditioning levels) in key brain areas regulating fear processing.
This included the ACC, Nacc, PVN, anterior BLA and lateral
amygdala. With the exception of the ACC, no preventative effects
were noted with either haloperidol or LY 379268. Glutamate
tissue content levels were also conserved with clozapine admin-
istration in the LC and BLA. Dopamine content was also brought
closer to fear conditioning levels in the LC and Nacc.
Interestingly, clozapine without ketamine administration
(FC+Cloz) had an effect similar to ketamine (FC+Ket), in terms
of glutamate content. Glutamate levels induced by fear condition-
Table 2. The dopac/dopamine metabolic ratios
..................................................................................................................................................
Brain areas Control FC FC+Cloz FC+Ket FC+Ket+Cloz
Median Range Median Range Median Range Median Range Median Range
ACC 1.35 2.19 0.79 49.95 0.93 1.79 0.64 0.51 0.82
* 2.98
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PLoS ONE | www.plosone.org 11 December 2007 | Issue 12 | e1360ing were significantly suppressed by clozapine in the central
amygdala (Fig. 6A) and locus coeruleus (data not shown), with a
trend in the basolateral amygdala (Fig. 6A). These results are
consistent with findings showing that clozapine directly suppresses
the glutamate system—suggestive of an anxiolytic effect
[69],[70]—and that clozapine is the most potent of the
antipsychotic agents in blocking NMDA receptor antagonist-
induced neurotoxicity [71],[72]. Given the similar neurochemical
effects of ketamine and clozapine, and given that ketamine alone
had a powerful effect on freezing behavior, it seems puzzling that
clozapine did not also have a potent effect on behavior. It is also
puzzling to consider why the neurochemical effects of ketamine
and clozapine administration do not predict their joint effects
when administered together. Since ketamine and clozapine both
decrease glutamate levels, we might expect that ketamine and
clozapine together should produce even further decreases in
glutamate levels. Yet in the basolateral amygdala and the locus
coeruleus, ketamine and clozapine administered together led
to relatively increased glutamate levels, comparable to the FC
group. As clozapine affects several neurotransmitter systems
[49],[73],[74], including glutamate, its reversal of ketamine’s
effect on glutamate could be due to its influence on other
neurotransmitters in other brain regions.
Taken together, clozapine appears to block the disruption of
fear processing by ketamine in several key brain areas. This effect
was not, however, reflected in the behavioral data; we found little
evidence to support the idea that clozapine maintains normal
freezing behavior following ketamine administration. In order to
reconcile the neural and behavioral data, we propose a
neurochemically-based conceptual model below.
Conceptual model
We adapt the model of Aleman and Kahn [24] and Reynolds [75]
to the current context in four key ways. First, we propose that
glutamate-mediated fear conditioning in the BLA drives freezing
behavior through the output nuclei of the CEA [76–78],[16].
Second, we hypothesize that dopamine-modulated c-aminobutyric
acid (GABA) inhibition in the CEA modifies the outputs of the
BLA [79]. Third, we interpret ketamine administration in terms of
a glutamate-mediated deficit in fear conditioning in the BLA [80–
82],[50]. Lastly, we propose that decreased dopamine turnover in
the CEA due to ketamine administration leads to increased GABA
inhibition of the BLA’s outputs in the CEA, leading to decreased
freezing behavior (see Fig. 7). The model can explain the major
features of our data as follows.
Fear conditioning
Glutamate content is increased in both amygdala nuclei as a result
of fear conditioning (Fig. 6A), but dopamine content is not affected
in either (Fig. 6B). As a result, output signals (glutamate) inducing
freezing behavior from the BLA via the CEA remain strong, as
dopamine inhibition of GABA interneurons remains intact. In
terms of cFos expression, fear conditioning elevates expression in
Figure 7. Conceptual model. A schematic drawing of our conceptual model depicting interactions between dopamine and glutamate in the
amygdala nuclei. The interactions between other brain areas studied and the amygdala conceptual model are also indicated. Dashed lines symbolize
inhibition, while solid lines represent stimulation. Lines between brain areas represent functional connectivity between the regions. Fear stimuli are
processed first by the basolateral amygdala (BLA), activating the glutamate system in this area, but do not affect dopamine levels in either the BLA or
central amygdala (CEA). Output signals inducing freezing behavior from the CEA are therefore strong via the glutamate pathway. Ketamine decreases
glutamate-related fear processing in the BLA and CEA and simultaneously elevates dopamine content (storage) in the CEA, by blocking dopamine
release via the dopamine D2 autoreceptor located on the cell body (possibly the VTA). The decreased dopamine release (together with the block of
glutamate transmission from the BLA to the CEA) blocks the fear-related outputs by means of increased GABA inhibition via intercalated cells
projecting onto the CEA. The net effect is weak output signals from the CEA and diminished freezing behavior. Clozapine, while blocking the effects
of ketamine on glutamate-related processing in the BLA and CEA, does nothing to prevent changes in dopamine levels. GABA-ergic intercalated cells
therefore continue to inhibit CEA and/or BLA and normal fear-conditioned behavior cannot be retained. Can chronic clozapine treatment renormalize
dopamine levels and lead to long-term remediation of negative symptoms in the animal model? ACC, anterior cingulate; DA, dopamine; LC, locus
coeruleus; Nacc, nucleus accumbens; PVN, paraventricular nucleus; VTA, ventral tegmental area
doi:10.1371/journal.pone.0001360.g007
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PLoS ONE | www.plosone.org 12 December 2007 | Issue 12 | e1360the BLA, but not the CEA. Interestingly, a study by Kleim et al.
[83] shows that cFos activity is directly related to learning of a skill,
and not only to the execution or maintenance of motor behavior.
This could indicate that the BLA is more concerned with
processing and storage of fearful memories, while the CEA is
mainly an output nucleus [76],[15],[77],[84],[31],[85].
Ketamine
It has been reported that ketamine administration, in addition to
acting on the glutamate system, also acts on the dopamine system,
perhaps through direct stimulation of the dopamine D2 receptor
[86]. The dopamine metabolic ratios in our study (Table 2)
indicate that the increase in dopamine content in the CEA after
ketamine administration is due to a decrease in turnover
(indicative of decreased release and a subsequent increase in
storage of the neurotransmitter in axon terminals). That is, less
dopamine is acting on the CEA and more is being stored axonally.
Ketamine also suppresses glutamate-related fear processing in the
BLA and CEA (Fig. 6A), in addition to simultaneously decreasing
dopamine turnover in the CEA. We therefore propose that this
decreased dopamine release liberates a tonic inhibition by GABA-
ergic neurons in the intercalated cells, leading to increased inhibition
of the glutamate signals from the BLA to the CEA. The net effect
is weak output signals from the CEA and consequently diminished
freezing behavior.
In agreement with this, Marowsky et al. [87] show that
dopamine D1 receptor (post-synaptic) activation disinhibits the
amygdala by inhibiting GABA-ergic mechanisms within the
intercalated cells. Interestingly, systemic application of dopamine
D1 agonists has been shown to retard or even reverse fear
extinction [88], whereas D1 antagonists block either the acquisi-
tion and/or expression of fear [89],[90]. Decreased dopamine
release through ketamine’s effects on the dopamine D2 auto-
receptor in our study may therefore re-activate the inhibitory
control of the intercalated cells on the CEA, resulting in behavioral
blockade (Fig. 7).
Antipsychotics
We hypothesized that clozapine but not haloperidol would
preserve normal fear-conditioned behavior by blocking the effects
of ketamine. We did not find evidence to support this notion. We
did, however, find that clozapine prevented the effect of ketamine
much more potently than haloperidol and LY 379268 in terms of
cFos expression in several brain areas (Fig. 4) and also that it
prevents decreased glutamate levels, in the BLA (Fig. 6A) and LC.
These observations would appear to predict normal freezing
behavior. In terms of the conceptual model, we suggest that
normal freezing behavior was not retained because clozapine did
not affect the dopamine (and glutamate) levels in the CEA that are
observed following ketamine administration. Dopamine turnover
and hence pre-synaptic release thereby remained low, leaving the
GABA-ergic inhibition of the CEA intact. This unchecked
inhibition of the pathway from the BLA to the CEA thus explains
why normal freezing behavior was not observed.
Predictions
What strategies could be used to restore normal fearful behavior? As
mentioned previously, ketamine acts primarily as an agonist at the
dopamine D2 autoreceptor, thereby inhibiting the release of
dopamine. We therefore propose two methods to counteract
ketamine’s effect on fear conditioning: 1) by using a selective
dopamine D2 antagonist to block ketamine’s actions on the
dopamine D2 autoreceptor or 2) by administering a selective
dopamine D1 agonist, which directly inhibits GABA-ergic function.
We chose to validate our animal model with clozapine and
haloperidol, as they are used in the clinical setting. Because
clozapine and haloperidol both act as antagonists at dopamine D2
receptors [91], we might suppose that they would block the effect
of ketamine on dopamine transmission at this receptor, and preserve
normal fear-conditioned behavior. However, both haloperidol and
clozapine also have affinities for the dopamine D1 receptor [91] and
subsequently block the dopamine that might eventually be released
as a result of D2 autoreceptor blockade, leaving any behavioral
blockade via the GABA-ergic cells in place. This could be one
explanation why even clozapine is not particularly effective in
treating negative symptoms of schizophrenia [92].
We also tentatively postulated the LY 379268 would prevent
ketamine’s actions, especially in forebrain areas. However, only a
small preventative effect was noted in freezing behavior, without
any significant changes in cFos expression in forebrain areas.
Comparable results were observed in a similar study in our lab
[61], where LY 379268 was unable to block ketamine-induced
deficits in pre-pulse inhibition. The authors attributed this
phenomenon to LY 379268’s failure to alter monoamine
neurotransmitter content, which could explain the lack of effect
on ketamine’s inhibition of cFos expression and behavior here.
Main conclusions regarding original hypotheses
In the Introduction, several hypotheses were outlined with regards
to our model of emotional blunting in schizophrenia. Most of the
hypotheses were confirmed, except with respect to LY 379268’s
possible prevention of ketamine effects, and more critically, the
potentially restorative effects of clozapine on fearful behavior. We
constructed a conceptual model to explain why clozapine did not
preserve normal freezing behavior, even though neural correlates
of fear conditioning indicated a positive outcome. We also
described improvements that may extend the model and allow
for full behavioral restoration. Taken together, the current study
supports the notion that glutamatergic hypofunctioning in the
amygdala and related brain areas underlies deficits in the
processing of fear, and could have implications for the mechanisms
underlying emotional blunting in schizophrenia. The present study
might therefore pave the way for future studies to explore novel
drug treatments of these notoriously drug-resistant symptoms, such
as selective dopamine D2 antagonists or selective D1 agonists
combined with clozapine.
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